Our expertise in phage and CIS display technologies coupled with our extensive automation capabilities, allows hits to be identified quickly.
Achieve a lead panel of characterised developable VHH binders in a minimum of 16 weeks from project initiation.
Developing Therapeutic VHH
A Tailored Approach
Starting from partner target nomination, we ensure to thoroughly understand the project concept. By doing this, our discovery alliances team develop and implement a project plan designed to mitigate risk early on. This de-risked approach from project outset sets the framework for joint success.